When the National Academies of Science, Engineering and Medicine released its FDA-funded report on cBHT in July 2020—which included a recommendation for across-the-board restrictions on compounded hormones—FDA issued a public statement saying the agency would base its next steps on compounded hormones on the NASEM report. That statement widely was interpreted to mean FDA will act to restrict compounded hormone therapy. We’re talking therapies that millions of patients rely on for their quality of life.
But a third-party analysis of the NASEM report shows it to be compromised by potential bias, conflicts of interest and bad science.










0 Comments